PMID- 32981301
OWN - NLM
STAT- MEDLINE
DCOM- 20210730
LR  - 20220325
IS  - 2093-5978 (Electronic)
IS  - 2093-596X (Print)
IS  - 2093-596X (Linking)
VI  - 35
IP  - 3
DP  - 2020 Sep
TI  - Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World 
      Multicenter Experience.
PG  - 587-594
LID - 10.3803/EnM.2020.687 [doi]
AB  - BACKGROUND: Vandetanib is the most widely used tyrosine kinase inhibitor for the 
      treatment of patients with advanced medullary thyroid cancer (MTC). However, only 
      limited data regarding its use outside clinical trials are available. We aimed to 
      evaluate the efficacy and safety of vandetanib in patients with advanced MTC in 
      routine clinical practice. METHODS: In this multicenter retrospective study, 12 
      patients with locally advanced or metastatic MTC treated with vandetanib at four 
      tertiary hospitals were included. The primary outcome was the objective response 
      rate (ORR) based on the Response Evaluation Criteria in Solid Tumors. The 
      progression-free survival (PFS), overall survival (OS), and toxicities were also 
      evaluated. RESULTS: Eleven patients (92%) had distant metastasis and 10 (83%) had 
      disease progression at enrollment. Partial response was observed in five patients 
      (ORR, 42%) and stable disease lasting >/=24 weeks was reported in an additional 
      five patients (83%). During the median 31.7 months of follow-up, disease 
      progression was seen in five patients (42%); of these, two died due to disease 
      progression. The median PFS was 25.9 months, while the median OS was not reached. 
      All patients experienced adverse events (AEs) which were generally consistent 
      with the known safety profile of vandetanib. Vandetanib was discontinued in two 
      patients due to skin toxicity. CONCLUSION: Consistent with the phase III trial, 
      this study confirmed the efficacy of vandetanib for advanced MTC in terms of both 
      ORR and PFS in the real-world setting. Vandetanib was well tolerated in the 
      majority of patients, and there were no fatal AEs.
FAU - Kim, Mijin
AU  - Kim M
AD  - Department of Internal Medicine, Biomedical Research Institute, Pusan National 
      University Hospital, Busan, Korea.
FAU - Yoon, Jee Hee
AU  - Yoon JH
AD  - Department of Internal Medicine, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea.
FAU - Ahn, Jonghwa
AU  - Ahn J
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
FAU - Jeon, Min Ji
AU  - Jeon MJ
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
FAU - Kim, Hee Kyung
AU  - Kim HK
AD  - Department of Internal Medicine, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea.
FAU - Lim, Dong Jun
AU  - Lim DJ
AD  - Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, Korea.
FAU - Kang, Ho-Cheol
AU  - Kang HC
AD  - Department of Internal Medicine, Chonnam National University Hwasun Hospital, 
      Hwasun, Korea.
FAU - Kim, In Joo
AU  - Kim IJ
AD  - Department of Internal Medicine, Biomedical Research Institute, Pusan National 
      University Hospital, Busan, Korea.
FAU - Shong, Young Kee
AU  - Shong YK
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
FAU - Kim, Tae Yong
AU  - Kim TY
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
FAU - Kim, Bo Hyun
AU  - Kim BH
AD  - Department of Internal Medicine, Biomedical Research Institute, Pusan National 
      University Hospital, Busan, Korea.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200922
PL  - Korea (South)
TA  - Endocrinol Metab (Seoul)
JT  - Endocrinology and metabolism (Seoul, Korea)
JID - 101554139
RN  - 0 (Piperidines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - YO460OQ37K (vandetanib)
RN  - Thyroid cancer, medullary
SB  - IM
MH  - Carcinoma, Neuroendocrine/*drug therapy/mortality/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Piperidines/adverse effects/*therapeutic use
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Quinazolines/adverse effects/*therapeutic use
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Thyroid Neoplasms/*drug therapy/mortality/pathology
PMC - PMC7520595
OTO - NOTNLM
OT  - Progression-free survival
OT  - Protein kinase inhibitors
OT  - Thyroid neoplasms
OT  - Toxicity
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2020/09/29 06:00
MHDA- 2021/07/31 06:00
PMCR- 2020/09/01
CRDT- 2020/09/28 03:42
PHST- 2020/04/21 00:00 [received]
PHST- 2020/07/16 00:00 [accepted]
PHST- 2020/09/28 03:42 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2021/07/31 06:00 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - EnM.2020.687 [pii]
AID - enm-2020-687 [pii]
AID - 10.3803/EnM.2020.687 [doi]
PST - ppublish
SO  - Endocrinol Metab (Seoul). 2020 Sep;35(3):587-594. doi: 10.3803/EnM.2020.687. Epub 
      2020 Sep 22.